Dallas, TX, March 27, 2016 --(PR.com
)-- Biomarkers are substances or activities that serve as markers of a specific biological activity. Biomarkers are extensively used in research and diagnostic applications. In addition to this, they are also used in the development of new drug therapies through the discovery of new target drugs. The global biomarkers market is expected to reach USD 62.0 billion by 2022, at a CAGR of 12.1% from 2016 to 2020. Factors such as increasing healthcare expenditure, increase in R&D funding, rising utility of biomarkers for diagnostic purposes, growing number of CROs, low-cost for conducting clinical trials in developing countries, and new initiatives for biomarker research are driving the growth of the biomarkers market. On the other hand, high capital investments and high cost-to-benefit ratio; regulatory and reimbursement challenges; and high cost of testing, sample collection, and storage are the major factors restraining the growth of this market.
On the basis of product type, the biomarkers market is segmented into consumables, services, and software. In 2016, the consumables product segment is expected to account for the largest share of the global biomarkers market. The large share of this segment can primarily be attributed to the increasing use of kit-based products for the testing of biomarkers and higher frequency of purchase of consumables as compared to other product segments.
On the basis of technology, the biomarkers market is categorized into safety biomarkers, efficacy biomarkers, and validation biomarkers. In 2016, the safety biomarkers segment is expected to account for the largest share of the global biomarkers market. Safety biomarkers are primarily used in trial phases 1 and 2. They enable the identification of toxicity in candidate drug molecules. Increasing research and development activities in pharmaceutical sector, to identify and validate new candidate therapeutic products is driving the demand for this market segment.
On the basis of applications, the biomarkers market is further segmented into diagnostics development, drug discovery and development, personalized medicine, disease-risk assessment, and other applications. In 2016, the diagnostics development segment is expected to account for the largest share of the global biomarkers market. Biomarkers play a significant role in the diagnosis of various diseases. Thus diagnostics development has major biomarker application compared to other applications due to increasing healthcare expenditure, which is improving access to new and high-quality diagnostics, and aiding growth of the diagnostics applications segment.
On the basis of indications, the biomarkers market is segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases. In 2016, the cancer disease indication segment is expected to account for the largest share of the global biomarkers market. Cancer biomarkers are extensively used in diagnostics, asses cancer progression, prognosis, and to devise treatment plans. They are also used in companion diagnostics products. Increasing incidence of cancer is driving the growth of this segment of the biomarkers market.
On the basis of regions, the biomarkers market is segmented into Asia-Pacific, Europe, North America, and Latin America and Middle East and Africa. In 2016, North America is expected to command the largest share of the global biomarkers market.
The biomarkers market is highly consolidated with few major companies having a large proportion of the market share. The key industry players in the global biomarkers market are QIAGEN N.V, PerkinElmer, Inc, Merck & Co, Inc. Bio-Rad Laboratories, Enzo Biochem, Inc., EKF Diagnostics Holdings, plc, Meso Scale Diagnostics, LLC, Singulex, Inc., Cisbio Bioassays, Biosims Technologies, and Signosis, Inc.
Data Bridge Market Research is providing a release offer to the first few clients a discount of 10% on this report, additionally 30 days of free customization is also included in this report. In case of requirement a presentation can also be bundled with this report including important graphs and charts. Procedure and patient data is also available though it may incur some additional charges.
For a free sample of this report please visit
Or Mail at